228 related articles for article (PubMed ID: 26503349)
1. A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.
Uguen A; Talagas M; Costa S; Duigou S; Bouvier S; De Braekeleer M; Marcorelles P
Diagn Pathol; 2015 Oct; 10():195. PubMed ID: 26503349
[TBL] [Abstract][Full Text] [Related]
2. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
3. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors.
Garola R; Singh V
Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802
[TBL] [Abstract][Full Text] [Related]
4. A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors.
Redon S; Guibourg B; Talagas M; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2018; 26(10):714-720. PubMed ID: 28362709
[TBL] [Abstract][Full Text] [Related]
5. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
6. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
7. Reevaluation of established and new criteria in differential diagnosis of Spitz nevus and melanoma.
Ritter A; Tronnier M; Vaske B; Mitteldorf C
Arch Dermatol Res; 2018 May; 310(4):329-342. PubMed ID: 29417221
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
10. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma.
Hilliard NJ; Krahl D; Sellheyer K
J Cutan Pathol; 2009 Jul; 36(7):753-9. PubMed ID: 19519606
[TBL] [Abstract][Full Text] [Related]
11. p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma.
Oaxaca G; Billings SD; Ko JS
J Cutan Pathol; 2020 Sep; 47(9):815-823. PubMed ID: 32330325
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
13. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
[TBL] [Abstract][Full Text] [Related]
14. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
15. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
16. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi.
Kucher C; Zhang PJ; Pasha T; Elenitsas R; Wu H; Ming ME; Elder DE; Xu X
Am J Dermatopathol; 2004 Dec; 26(6):452-7. PubMed ID: 15618925
[TBL] [Abstract][Full Text] [Related]
17. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of p16 in desmoplastic melanoma.
Blokhin E; Pulitzer M; Busam KJ
J Cutan Pathol; 2013 Sep; 40(9):796-800. PubMed ID: 23808580
[TBL] [Abstract][Full Text] [Related]
19. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry of p16 in nevi of pregnancy and nevoid melanomas.
Koh SS; Roehmholdt BF; Cassarino DS
J Cutan Pathol; 2018 Dec; 45(12):891-896. PubMed ID: 30178478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]